GERN
Geron Corporation
$1.17
-$0.04(-3.31%)
40
Overall
60
Value
18
Tech
42
Quality
Market Cap
$695.81M
Volume
9.50M
52W Range
$1.04 - $2.01
Target Price
$3.40
Company Overview
| Mkt Cap | $695.81M | Price | $1.17 |
| Volume | 9.50M | Change | -3.31% |
| P/E Ratio | -8.3 | Open | $1.21 |
| Revenue | -- | Prev Close | $1.21 |
| Net Income | $-83.5M | 52W Range | $1.04 - $2.01 |
| Div Yield | N/A | Target | $3.40 |
| Overall | 40 | Value | 60 |
| Quality | 42 | Technical | 18 |
No chart data available
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Latest News
Geron Earnings Call Highlights Growth, Pricing Pressures
TipRanks Auto-Generated Newsdesk•17 days ago
Needham Remains a Buy on Geron (GERN)
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
Analysts Are Bullish on These Healthcare Stocks: Geron (GERN), Regeneron (REGN)
Catie Powers•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GERN | $1.17 | -3.3% | 9.50M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |